vepoloxamer (MST-188) / Savara - LARVOL DELTA

Effects of poloxamer 188 on traumatic brain injury. (PubMed, Brain Behav Immun Health) - "These articles have shown direct protective effects of P188 on brain tissue following TBI, including restitution of the increase cell membrane permeability, attenuation of neuronal necrosis and apoptosis, improvement of mitochondrial viability, reduction in axonal disruption, and restoration of the blood brain barrier. In animals, P188 has been shown to improve sensorimotor functions, as well as spatial learning and memory."

Journal • Review • CNS Disorders • Vascular Neurology

Vepoloxamer improves functional recovery in rat after traumatic brain injury: A dose-response and therapeutic window study. (PubMed, Neurochem Int) - "In addition, our data demonstrated that the dose of 300 mg/kg of Vepoloxamer administered at 2 h, 4 h, 1 day, or 3 days post injury significantly improved neurological function compared with vehicle, whereas Vepoloxamer administered at 2 h or 4 h post injury significantly improved cognitive function compared with the 1-day and 3-day treatments, with the most robust effect administered at 2 h post injury. The present study demonstrated that Vepoloxamer improves functional recovery in a dose-and time-dependent manner, with therapeutic efficacy compared with vehicle evident even when the treatment is initiated 3 days post TBI in the rat."

Journal • Preclinical • CNS Disorders • Vascular Neurology

Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage. (PubMed, Front Neurol) - "Combination treatment with tPA and Vepoloxamer at 4 h after stroke onset effectively reduces ischemic neurovascular damage by accelerating thrombolysis and reducing ischemia and tPA potentiated side effects in the aged rats. This funding suggests that the combination treatment with tPA and Vepoloxamer represents a promising strategy to potentially apply to the general population of stroke patients."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Ischemic stroke

Can red blood cell function assays assess response to red cell-modifying therapies? (PubMed, Clin Hemorheol Microcirc) - "This study demonstrates that the standardized flow adhesion and mechanical fragility biomarkers described here may be useful tools to predict clinical responders to RBC-modifying therapies."

Journal • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

[VIRTUAL] CIRCULATING TUMOR CELLS DETECTED WITH MICROCAVITY ARRAY PREDICT CLINICAL OUTCOME IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (AASLD 2020) - "The overall survival was significantly shorter in ALB mRNA-positive patients than in ALB mRNA-negative patients (MST 188 days vs not reached; P = 0.037)... The MCA system has a potential to isolate CTCs from HCC with high sensitivity. And, mRNA expression from isolated CTCs could be measured. Positive CTC or CTC-derived ALB mRNA could help predict the prognosis of HCC patients."

Clinical • Clinical data • Fibrosis • Gastroenterology • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Solid Tumor • CTCs • EPCAM • GPC3 • PTPRC

Effects of Intravenous Infusion of Vepoloxamer on Left Ventricular Function in Dogs with Advanced Heart Failure. (PubMed, Cardiovasc Drugs Ther) - "Intravenous VEPO improves LV function for at least 1 week after infusion. The benefits can be extended with pulsed VEPO therapy. The results support development of VEPO for treating patients with acute on chronic HF."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Psychiatry

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - P3; N=388; Completed; Sponsor: Mast Therapeutics, Inc.; Recruiting ➔ Completed

Trial completion • Biosimilar • Demo Pain • Gene Therapies

Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke. (PubMed, Stroke) - "Conclusions- The combination treatment with vepoloxamer and tPA exerts potent thrombolytic effects in rats subjected to acute ischemic stroke. Vepoloxamer reduces tPA-aggravated prothrombotic effect of platelet-derived exosomes on cerebral endothelial cells, which may contribute to the therapeutic effect of the combination treatment."

Journal

Treatment of traumatic brain injury with vepoloxamer (Purified Poloxamer 188). (PubMed, J Neurotrauma) - "In summary, vepoloxamer treatment initiated 2 h post injury provides neuroprotection and anti-inflammation in rats after TBI and improves functional outcome, indicating that vepoloxamer treatment may have potential value for treatment of TBI. Further investigation of the optimal dose and therapeutic window of vepoloxamer treatment for TBI and the mechanisms underlying beneficial effects are warranted."

Journal

The Combination of Tissue Plasminogen Activatorand Vepoloxamer Results in Sustained Neuroprotection in Aged Rats After Embolic Stroke (ISC 2019) - "The combination of tPA and Vepoloxamer did not increase the mortality rate nor the incidence of cerebral hemorrhage compared with saline or tPA monotherapy. In conclusion, our data demonstrated that the adjuvant treatment with Vepoloxamer and tPA amplifies the therapeutic efficacy of low-dose tPA in aged rats after embolic stroke without increasing the incidence of hemorrhagic transformation."

Preclinical